A Carrier-Free Triple-Drug Co-Assembled Nanoformulation for Synergistic Treatment of Cerebral Ischemia-Reperfusion Injury
ACS Applied Materials & Interfaces · 2025
DOI: 10.1021/acsami.5c05882 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2025. Verfasst von Yajie Guo und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Chongqing Medical University, Chongqing 400016, China. Hauptthemen laut MEDLINE: Reperfusion Injury, Ginsenosides, Benzofurans, Neuroprotective Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Science and Technology Foundation of Shenzhen City, Natural Science Foundation of Chongqing Municipality, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Cerebral ischemia-reperfusion injury (CIRI), a critical complication arising from the recanalization of blood flow to the ischemic region of the brain following an ischemic stroke, poses significant challenges in clinical management due to the lack of efficacious therapeutic interventions. This condition markedly impacts the patient prognosis and quality of life. Herein, we developed a carrier-free triple-drug co-assembled nanoformulation, designated as SRPNNPs, to achieve safe and efficient treatment of CIRI. SRPNNPs were prepared by co-assembly of two natural plant-derived small molecule drugs, including ginsenoside Rb1 (Rb1) and 3-n-butylphthalide (NBP), along with probucol (PB). To enhance the capability to cross the blood-brain barrier (BBB), SRPNNPs were further modified with polysorbate 80 (PS 80). Intravenously administered SRPNNPs can adsorb apolipoproteins in circulation, thereby facilitating specific binding to lipoprotein receptors on the cerebral vascular endothelial cells, which promotes their transport across the BBB. Furthermore, SRPNNPs are enriched to the CIRI region and are subsequently internalized by neurons and microglia, where they exert synergistic antioxidant, anti-inflammatory, and neuroprotective effects, thereby achieving effective treatment of CIRI. Overall, our work presents a simple and promising strategy for the targeted treatment of CIRI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medical Sciences, Chongqing Medical University, Chongqing 400016, China.
- Center for Neuroscience Research, Chongqing Medical University, Chongqing 400010, China.
- Institute of Cytology, Russian Academy of Science, Tikhoretskiy Prospect 4, 194064 St. Petersburg, Russia.
- JinFeng Laboratory, Chongqing 401329, China.
- Key Laboratory for Biorheological Science and Technology of Ministry of Education, National Local Joint Engineering Lab for Vascular Implants, College of Bioengineering, Chongqing University, Chongqing 400044, China.
ORCID-Profile: Zhenghuan Zhao, Guixue Wang
Förderung
- Science and Technology Foundation of Shenzhen City
- Natural Science Foundation of Chongqing Municipality
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Science and Technology Innovation Project of Jinfeng Laboratory
Zitieren
APA
Guo, Y., Jia, M., He, Q., Zeng, J., Zhang, Y., Gao, Y., Zhao, Z., Malashicheva, A., Miao, W., Zhao, J., Wang, G., & Wang, Y. (2025). A Carrier-Free Triple-Drug Co-Assembled Nanoformulation for Synergistic Treatment of Cerebral Ischemia-Reperfusion Injury. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c05882
Vancouver
Guo Y, Jia M, He Q, Zeng J, Zhang Y, Gao Y, et al. A Carrier-Free Triple-Drug Co-Assembled Nanoformulation for Synergistic Treatment of Cerebral Ischemia-Reperfusion Injury. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.5c05882
BibTeX
@article{Guo2025,
author = {Guo, Yajie and Jia, Mengjie and He, Qi and Zeng, Jieying and Zhang, Yuxin and Gao, Yan and Zhao, Zhenghuan and Malashicheva, Anna and Miao, Wenjun and Zhao, Jing and Wang, Guixue and Wang, Yi},
title = {A Carrier-Free Triple-Drug Co-Assembled Nanoformulation for Synergistic Treatment of Cerebral Ischemia-Reperfusion Injury},
journal = {ACS Applied Materials & Interfaces},
year = {2025},
doi = {10.1021/acsami.5c05882}
}
EUVIMED